LearnGlossaryMarketStocksSuperinvestorsSign in

IVVD

Invivyd, Inc.

Healthcare · $235M market cap

Verdict

We can't put a fair value on IVVD right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-39.1% a year✗
Sales growth110.5% a year✓
Free cash flow growth—?
Return on invested capital-44.1%✗

Follow IVVD

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Aug 31, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Sheffield Ian

director · 2026-08-31

Award

$95K

About Invivyd, Inc.

Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works